Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Personalized-Phage Against E. Coli with IV Antibiotic to Knockout Stable Biofilms in Urinary Tract Infections

Objectif

P-PEAKS UTI is a multicenter, intercontinental Phase II randomized controlled trial evaluating the safety, efficacy, and feasibility of personalized bacteriophage therapy in combination with intravenous beta-lactam antibiotics for the secondary prevention of recurrent urinary tract infections (rUTIs) caused by Escherichia coli in female patients . The study will recruit 216 participants across 9 clinical sites, including high-risk renal transplant recipients. Phage therapy or placebo will be administered via oral (day 1 and 2), bladder instillation (day 1), and topical/vaginal routes all over 5 days. Both arms will receive a single dose of IV antibiotic on day 2 to enhance bacterial clearance and biofilm disruption. This combination strategy leverages potential synergy between phages and antibiotics, aiming to reduce recurrence rates and antibiotic use.
The project integrates AI-based phage-host prediction, GMP and Magistral phage production, and standardized susceptibility testing aligned with EUCAST guidelines. It investigates phage immunogenicity, microbiome dynamics, and pharmacokinetics/pharmacodynamics to inform future personalized antimicrobial strategies.
P-PEAKS UTI also performs health economic analysis to quantify cost-effectiveness of phage therapy in urinary tract infections compared to standard antibiotic treatment and engages patients to address stigma and acceptability of phage therapy. It contributes to regulatory science by generating quantifiable, replicable data to support future market authorization of phage therapies and informs policy through collaboration with EMA and national agencies.
In the longer term, we aim to deliver an improved, effective and meaningful solution for the prevention of recurrent UTIs in female patients improving their health outcomes and quality of life. This will also strengthen healthcare systems’ capacity to combat antimicrobial resistance and empower citizens with knowledge-based alternatives to antibiotics.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-RIA - HORIZON Research and Innovation Actions

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) HORIZON-HLTH-2025-01

Voir tous les projets financés au titre de cet appel

Coordinateur

UNITY HEALTH TORONTO
Contribution nette de l'UE
€ 2 428 962,33
Coût total
Aucune donnée

Participants (19)